No Data
No Data
Nuvalent Doses First Subject in Phase Ia/Ib Trial of Lung Cancer Treatment
Express News | Nuvalent Announces First Patient Dosed in Heroex-1 Phase 1a/1B Clinical Trial of Nvl-330, Its Novel Her2-Selective Inhibitor
Nuvalent Insider Sold Shares Worth $403,621, According to a Recent SEC Filing
Nuvalent To Present Updated Data From ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And ALKOVE-1 Phase 1/2 Clinical Trial Of NVL-655 at ESMO Congress 2024
Express News | Nuvalent Announces Promotion of Henry Pelish, Ph.d. to Chief Scientific Officer
Nuvalent(NUVL.US) Officer Sells US$219.69K in Common Stock
$Nuvalent(NUVL.US)$ Officer Miller Deborah Ann sold 3,000 shares of common stock on Jul 8, 2024 at an average price of $73.23 for a total value of $219.69K.Source: Announcement What is statement of
No Data